As approximately 15% of individuals with an APOL1 high-risk genotype will develop ESKD (Friedman and Pollak 2021), identifying genetic modifiers for the risk variants can improve our understanding of the incomplete penetrance seen in APOL1 kidney disease. This evidence concerns the gene APOL1 and kidney disorder.